Express News | A fire broke out in the National Assembly building in South Korea, leading to the evacuation of over 480 people.
Did Novo-Nordisk A/S fall, leaving Eli Lilly and Co to dominate the weight loss medication market?
Novo-Nordisk A/S faced a "Waterloo," with new drug effects falling short of expectations, causing a dramatic drop in stock prices. The landscape of the weight loss drug market is quietly changing; will Eli Lilly and Co become a sole oligopoly?
News Highlights: Top Company News of the Day - Friday at 7 PM ET
Novo Nordisk Stock Crashes on Obesity Drug Data. It's a Win for Eli Lilly. -- Barrons.com
FDA Approves First Medication for Obstructive Sleep Apnea
Eli Lilly Says FDA Approves Zepbound for Obstructive Sleep Apnea in Adults With Obesity
Express News | Eli Lilly and Co's weight loss drug Zepbound has been approved for the treatment of sleep apnea.
Express News | US FDA Approves Eli Lilly's Zepbound for Moderate-to-Severe Obstructive Sleep Apnea in Adults With Obesity - Website
Stocks to Watch Friday: Trump Media, Novo Nordisk, Eli Lilly, Tesla -- WSJ
Sector Update: Health Care Stocks Rise in Late Afternoon Trading
Pfizer Gets FDA Accelerated Approval for Braftovi
Sector Update: Health Care
Jefferies Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $994
Leerink Partners Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Announces Target Price $970
Bernstein Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,100
There's a New Obesity King -- Heard on the Street -- WSJ
Trending Stocks Today | My Size Surges 333.33%
December 20th - US stocks trending in regular trading hours.Gainers: $My Size(MYSZ.US)$ surges 333.33% to $5.85 with a turnover of $611.42 million. $Helius Medical Technologies(HSDT.US)$ soars 74.35%
EXCLUSIVE: Weight-Loss Market Experts Scoop Up Novo Nordisk Stock After Worst Drop Since 2002 Following Drug Trial Miss
J.P. Morgan's Top Healthcare Stocks for 2025
Benzinga Market Summary: Novo Nordisk Falls On Weight Loss Data, Shares Of Competitor Lilly Rise, S&P Continues Higher